Incidence of Hepatic Hemangiomatosis in Patients With Cutaneous

Status Completed

Clinical Trial Summary

This study will attempt to determine how common liver hemangiomas are in children with infantile hemangiomas by comparing liver ultrasound results in patients with 1-4 cutaneous hemangiomas, 5 or more cutaneous hemangiomas, or at least 1 large hemangioma versus ultrasound results in children without hemangiomas. Other objectives of the study include identifying specific risk factors in patients who have liver hemangiomas and identifying risk factors in children with symptomatic liver hemangiomas.

Clinical Trial Description

Hemangioma of infancy is the most common tumor of childhood occurring in 4% to 10% of infants. While most hemangiomas are benign in behavior and involute spontaneously, some can cause significant morbidity due to their location and size. In addition, some hemangiomas may be associated with extracutaneous hemangiomas that result in significant morbidity. Certain "high risk" hemangiomas of infancy, specifically multiple cutaneous hemangiomas or a solitary large hemangioma, have been associated with hepatic hemangiomatosis; however, the exact number or size of the cutaneous lesions at which the risk increases and the protocol for evaluating these patients remain controversial. The true prevalence of hepatic hemangiomatosis is unknown since there have been no large scale prospective studies evaluating clinically asymptomatic patients with cutaneous hemangiomas for the presence of hepatic hemangiomatosis.

One of the primary objectives of this study is to determine the incidence of hepatic hemangiomatosis in patients with hemangiomas of infancy by comparing hepatic ultrasound imaging results of patients with 1-4 cutaneous hemangiomas, 5 or more cutaneous hemangiomas, or at least 1 large hemangioma >30 cm2 versus imaging results in patients without cutaneous hemangiomas. The study will also attempt to identify specific risk factors associated with the development of hepatic hemangiomatosis and to identify associated risk factors in patients with clinically symptomatic hepatic hemangiomatosis. ;

Study Design

Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening

Related Conditions & MeSH terms

Hemangioma

Clinical Trial Details

NCT number	NCT00374335
Study type	Interventional
Source	Children's Mercy Hospital Kansas City
Contact
Status	Completed
Phase	N/A
Start date	September 2006
Completion date	December 2009

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01685398` - Topical Timolol for Superficial Infantile Hemangioma	Phase 3
Withdrawn	`NCT00974129` - A Study of CCCTC-binding Factor (CTCF) in Infantile Hemangiomas	N/A
Recruiting	`NCT03331744` - Clinical Characteristics of Infantile Hemangioma
Completed	`NCT02342275` - Efficacy and Safety of Propranolol Versus Atenolol on the Proliferative Phase of Infantile Hemangioma	Phase 3
Completed	`NCT00433940` - Immune Suppression Of Infants Treated With Steroids	N/A
Completed	`NCT04065217` - The Effectiveness of Diode Laser 980-nm in Iraqi Face Hemangioma: a Randomized Within Patients Trial	N/A
Terminated	`NCT01743885` - Efficacy and Safety of Propranolol Versus Acebutolol on the Proliferative Phase of Infantile Hemangioma	Phase 3
Terminated	`NCT00555464` - Clinical Trial of Vincristine vs. Prednisolone for Treatment of Complicated Hemangiomas	Phase 2
Completed	`NCT00394888` - Hemangioma Associated With High Rates of Morbidity	N/A
Completed	`NCT05327309` - Role of Propranolol as Compared to Bleomycin in Management of Hemangioma	N/A
Completed	`NCT02145884` - Topical Timolol Gel for the Treatment of Infantile Hemangiomas	Phase 2
Completed	`NCT04077515` - Safety and Efficacy of Low-dose Sirolimus to Kaposiform Hemangioendothelioma	Phase 4
Completed	`NCT02731287` - Topical Timolol for Infantile Hemangioma in Early Proliferative Phase	Phase 2
Recruiting	`NCT01147601` - Topical Timolol 0.5% Solution for Proliferating Infantile Hemangiomas	Phase 0
Completed	`NCT01908972` - The Safety and Efficiency of Propranolol as an Initial Treatment for Pediatric Hemangioma	Phase 4
Completed	`NCT00540566` - Optical Biopsy of Human Skin in Conjunction With Laser Treatment
Completed	`NCT00001417` - Direct Injection of Alcohol for the Treatment of Spinal Tumors	N/A
Completed	`NCT00004436` - Randomized Study of Hormonal Regulation of Infantile Hemangioma	N/A
Recruiting	`NCT02496013` - Clinical Translation of a Novel Albumin-Binding PET Radiotracer 68Ga-NEB	Phase 1
Completed	`NCT01072045` - Comparative Study of the Use of Beta Blocker and Oral Corticosteroid in the Treatment of Infantile Hemangioma	Phase 2

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Incidence of Hepatic Hemangiomatosis in Patients With Cutaneous Hemangiomas

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms